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Abstract 1 
The use of doping agents are evident within competitive sport in senior and junior age groups, 2 
where they are taken by non-elite as well as elite participants.  They are also taken in non-3 
sporting contexts by individuals seeking to ‘improve’ their physique through an increase in muscle 4 
and/or decrease in fat mass.  Whilst attaining accurate data on the prevalence of their use has 5 
limitations, studies suggest the illicit use of doping agents by athletes and non-athletes may be 1 6 
– 5% in the population and greater than 50% in some groups; with the prevalence being higher in 7 
males.  There is conclusive evidence that some doping agents are anabolic and ergogenic. There 8 
is also evidence that the use of doping agents such as: anabolic androgenic steroids; growth 9 
hormone and other anabolic agents; erythropoietin; and stimulants conveys considerable health 10 
risks that include, but are not limited to: cardiovascular disease, diabetes, cancer, mental health 11 
issues, virilisation in women, and the suppression of naturally produced androgens in men. This 12 
review will outline the anabolic, ergogenic and health impacts of selected doping agents and 13 
methods that may be used in both the sporting and physique development contexts.  It also 14 
provides a brief tabulated overview of the history of doping and how doping agents may impact 15 
upon the analyses of clinical samples.  16 
17 
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Introduction 1 
Sport and physical activity are widely encouraged by governments and health authorities for their 2 
perceived benefits to health and quality of life.  Conversely, illicit drug use is deemed to have a 3 
negative impact on health and adversely affect society. However, since some drugs are known to 4 
augment physical performance and adaptations to exercise training, these two contrasting areas 5 
can intersect.  6 
 7 
In sport the use of illicit drugs comes under the category of ‘doping’ with the relevant sports 8 
governing bodies pursuing strategies to prevent the use of banned substances.  Doping is used in 9 
sport and exercise contexts for a number of reasons, including the desire to win and to improve 10 
aesthetic appearance.  Sports are governed by rules and codes, including those relating to the 11 
prohibition of doping.  Perhaps the most well-known of these is the ‘World Anti-Doping Code’,1  12 
which is implemented by the World Anti-Doping Agency (WADA) and WADA publish a list of 13 
prohibited substances and prohibited methods.2 Doping substances and methods are included on 14 
the WADA prohibited list if they meet two of the following three criteria:3 15 
(i) Evidence that it has the potential to enhance sport performance; 16 
(ii) Use of the substance or method represents a health risk; 17 
(iii) Use of the substance or method violates the spirit of the sport. 18 
 19 
The WADA list clusters its doping categories into: ‘Substances and Methods Prohibited at All 20 
Times (in- and out-of competition)’; ‘Substances and Methods Prohibited In-Competition’; and 21 
‘Substances Prohibited in Particular Sports’ (Table 1). As a broad generalisation for this distinction 22 
the ‘Substances and Methods Prohibited at All Times (in- and out-of competition)’ have potential 23 
benefits in terms of enhancing adaptation to training and either directly to or as a consequence of 24 
these augmented adaptations to improve performance in competition.  Whereas ‘Substances and 25 
Methods Prohibited In-Competition’ are likely to enhance the immediate short term performance 26 
of the body by augmenting its ability to meet the demands of the exercise and thereby perform 27 
better.  Furthermore, some substances are prohibited under the WADA code in ‘Particular Sports’ 28 
if they convey benefits or hazards in specific sports but not others, such as alcohol in motor 29 
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sports. WADA publishes a list of sport organisations and countries who comply with the WADA 1 
anti-doping code and are subject to WADA testing.4 However, it should be noted that many 2 
professional sports such as the National Football League (NFL) (American Football/Gridiron)5 3 
some boxing federations, and many body-building type sports do not comply fully with the WADA 4 
code and its anti-doping regulations.   5 
 6 
In the wider context, the use of such drugs extends beyond regulated elite sport, into lower levels 7 
and younger age groups, as well as occurring outside of the sporting context; where they may be 8 
used to enhance the development of a person’s physique for reasons of aesthetics and physical 9 
presence.6 Consequently the health issues associated with the use of such drugs permeates 10 
society beyond the sporting elite.  Additionally, not all ergogenics are banned from sport, 11 
examples being caffeine, creatine and bicarbonate, all of which have strong research evidence for 12 
their efficacy. 7-11 This review will briefly present some of the key events in the history of doping, 13 
consider current doping prevalence and then review the performance and health issues of the 14 
WADA doping categories.  15 
 16 
Methods for Literature Review 17 
The published scientific literature was searched using key words in databases, primarily Pubmed.  18 
Additionally, literature and documents were searched from key sites, such as the WADA.  To 19 
ensure currency of data and information, those articles published within the last 10 years were 20 
preferentially referred to over older publications.  When the identified literature referred to a key 21 
publication that had not been identified in our searches this article was located directly, likewise 22 
where the original search had been refined to reviews, key original data articles cited in the 23 
reviews were downloaded.  Where applicable, confirmed examples were sought from the popular 24 
press. 25 
For note, the nomenclature and level of detail applied to peptide hormones in the published 26 
literature varied based on the context of the information provided.  Within this review when 27 
discussing the use of various hormones, such as Erythropoietin (EPO), Growth Hormone (hGH), 28 
Luteinizing Hormone (LH) and Chorionic Gonadotrophin (CG), the prefix ‘h’ indicates the ‘human’ 29 
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form of the hormone and ‘r’ indicates the recombinant synthetic version, with ‘rh’ indicating a 1 
recombinant version of the human form.  Hence the terminology may vary in places depending on 2 
the specific form of the hormone being discussed and the information provided in the source 3 
material. 4 
 5 
The physiological basis for doping in sport and exercise 6 
Sport and exercise initiate both short-term acute responses and longer term adaptations.  The 7 
short-term acute responses include elevations in heart rate and cardiac output, redistribution of 8 
blood flow, increased pulmonary ventilation and endocrinological responses.  These responses 9 
enhance the body’s ability to cope with the immediate demands of the current exercise bout, for 10 
example through the facilitation of oxygen delivery and its utilisation by the muscles.  The longer-11 
term adaptations, such as structural and physiological changes to the skeletal musculature, 12 
cardiovascular system and haematology, enhance the body’s ability to cope with the demands of 13 
subsequent exercise, for example through an increased capacity to deliver and utilise oxygen or 14 
an increase in contractile proteins of the muscle that thereby increase the amount of force that 15 
they can exert. Such adaptations would be seen as improvements in ‘fitness’ and enable the 16 
person to potentially achieve a higher level of performance in subsequent exercise bouts or 17 
events. 18 
 19 
Doping is used to augment these responses and adaptations, thereby elevating what the person 20 
can achieve to a level above that attainable by training alone.  Due to the specific demands of 21 
each sport, the prevalence of different drugs and doping procedures will differ accordingly, as they 22 
are used to target specific aspects of the fitness needed by the performer in that particular activity.  23 
Additionally, as previously indicated, some doping practises are used specifically to enhance the 24 
physique of an individual, often to gain muscle mass and/or lose body fat: and whilst for sports 25 
performers such outcomes may benefit their strength, power and endurance, for others it is the 26 
enhanced physique that is the primary objective. 27 
 28 
A Brief History of Doping in Sport 29 
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Historically, the second half of the 19th Century saw the start of what has become the epidemic 1 
problem of doping in sport and exercise at all levels of competition.  In the first half of the 20th 2 
Century (up until the end of World War II) doping expanded with programs aimed at the individual 3 
and administration controlled by the athlete themselves or by their coach or doctor.  Doping at this 4 
time was generally confined to the elite level of sport.  Post World War II, doping expanded 5 
significantly with systemic team doping programs emerging.  In response to the increased 6 
incidence and adverse outcomes, doping controls were first introduced in the late 1960’s; partly 7 
due to the outcry resulting from the first televised doping related death. 8 
 9 
Sport related drug use has significantly influenced competition since the mid 20th century.  The 10 
1960’s and 70’s saw the wide use of amfetamines in sport; the 1980’s has been described as the 11 
anabolic steroid and cortisone era; the 1990’s as the human Growth Hormone (hGH) and 12 
erythropoietin (EPO) era; and more recently the use of peptides has become widespread.  Today 13 
we generically classify such performance enhancing drugs according to terms such as “anabolics” 14 
and “stimulants” to describe the general desired effect of their administration. 15 
 16 
With doping control, comes the introduction of drugs to “cheat” the system.  The reported instance 17 
of evasive measures became prevalent after the 1980’s when the first assay to detect 18 
testosterone in urine was developed.  Despite these control measures and awareness of the risks 19 
of sport related drug use, doping in sport remains endemic; transgressing all levels of activity. 20 
 21 
At the elite level, infamous systematic doping scenarios and individual cases are cited throughout 22 
sporting history.  The German Democratic Republic (GDR) government administered doping 23 
program of its athletes, particularly its female athletes, contributed to their domination of Track & 24 
Field and Swimming events for the two decades spanning the 1970s and 1980s.12  There are also 25 
numerous highly publicised individual cases including those of Ben Johnson (Canada) who was 26 
stripped of the Gold Medal for the 100m at the 1988 Seoul Olympics when it was reported that he 27 
tested positive for stanozolol.  Furthermore, it is interesting to recall that of the eight runners in 28 
this infamous race, five of the other finalists either gave positive samples or were involved in 29 
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some way in doping scandals at some stage in their careers.  Other more recent examples 1 
include: Marion Jones who won five medals at the 2000 Sydney Olympics but was stripped of all 2 
these medals, when having been implicated by the highly publicised Bay Area Laboratory 3 
Cooperative (BALCO) investigation, she admitted in 2007 to using performance-enhancing drugs; 4 
and Lance Armstrong, who won the Tour de France cycling event on seven consecutive 5 
occasions (1999 – 2005) but was stripped of these titles in 2013 having been investigated by 6 
USADA and admitting to doping during a television interview by ‘Oprah’. For the interested reader 7 
a brief tacit history describing the expansion of doping in sport is provided in Table 2.   8 
 9 
The prevalence of doping 10 
Sport related drug use 11 
The prevalence of doping can be indicated through surveys or by the testing of participants, but 12 
both methods have inherent problems.  For example, survey data has limitations relating to 13 
differences in the definitions of doping and the taking of ‘banned’ substances for social rather than 14 
performance enhancing reasons, as well as a reliance upon honest self-reporting of an illicit 15 
activity.13  Whereas the clinical testing of a blood or urine sample may fail to identify doping 16 
cheats if the timing of sample collection does not coincide with the window of time when the 17 
substance or its metabolites are present within the individual’s sample.   18 
 19 
Whilst the highly publicised cases highlighted above create awareness through the media, 20 
quantifying the actual prevalence of sport related drug use is more problematic and incurs the 21 
aforementioned limitations.  However, as an initial indication, WADA report the results of 269,878 22 
samples analysed in 2013, of which 5,962 (2.21%) indicated either an ‘adverse analytical finding’ 23 
or ‘atypical finding’.14 Of these: 63.0% were due to anabolic agents; 10.1% stimulants; 7.5% 24 
diuretics and other masking agents; 6.3% glucocorticosteroids; 3.8% peptide hormones, growth 25 
factors and related substances; and 3.6% cannabinoids; with all other categories contributing 26 
<3% to the total adverse/atypical findings and their combined total being about6% of all adverse 27 
or atypical results.(Figure 1)  The relatively recent introduction of testing blood samples has 28 
added to these results with a study that included the samples of 2,737 international track and field 29 
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athletes, mainly endurance athletes, from whom blood samples were collected indicating the 1 
prevalence of blood doping (any method that increases red cell mass and enhances oxygen 2 
transport) to be 14%, but with considerable variation in prevalence between nationalities.15 3 
 4 
Doping violations have also been reported in Paralympic sport, albeit with a relatively low 5 
prevalence of <1%  and when such violations are detected it is most commonly for anabolic 6 
agents, with sports such as powerlifting having the highest prevalence.16 At lower levels of sport 7 
the reported prevalence includes: 43% Anabolic Androgenic Steroids (AAS) and 12% hGH or 8 
Insulin-like Growth Factor (IGF-I) in young male weight lifters.17  Indeed it is suggested that 4 - 6% 9 
of adolescent male athletes and 1.5 - 3.0% of adolescent female athletes will have used AAS at 10 
some time.18  11 
 12 
Non-sport related drug use 13 
In addition to sport specific doping, social drug use is also evident amongst athletes, and an 14 
Italian study indicated that 18% of all positive results were for cannabis and 7% for cocaine which 15 
whilst constituting a positive test, were likely to be cases of social drug use rather than for 16 
performance enhancing purposes.19 In May 2013, the WADA raised the in-competition threshold 17 
for marijuana (cannabis) tenfold to 150 ng/mL to avoid such use being included as a doping 18 
offence.20  Likewise, the results from a study that questioned members and junior members of 19 
German national teams from 43 different sports, indicated a 7% prevalence of illicit drug use, and 20 
a study of over two thousand German adolescents, in which 15.1% indicated that they had used a 21 
WADA banned substance, cannabis was the most prevalent (13.2%),21 followed by stimulants 22 
(2.4%), cocaine/heroin (2.2%) and Anabolic Androgenic Steroids (AAS) (0.7%).22   23 
 24 
What is also evident from other studies is that the use of doping agents is not confined to those 25 
involved in competitive sport, but are also used for aesthetic reasons and ‘body styling’ in young 26 
and adult males and females, notably for the aforementioned increase in muscle mass and/or fat 27 
reduction, with AAS being the most common drugs used.23-27 With scenarios such as the seizure 28 
of millions of doses of steroids and hGH by the US Drug Enforcement agency further indicating a 29 
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widespread illicit use of doping agents.23  Indeed, a Swedish study indicated that the use of AAS 1 
was more prevalent in society than in regulated sport and the use amongst Swedish high school 2 
pupils has been reported as 2.7% in males and 0.4% in females.28,29 This concurs with other 3 
studies in which prevalence rates for high-school-aged students range between 1% and 3% 4 
across several countries.30 Similar prevalence rates have been reported for tertiary education 5 
students from six developed countries, with a higher usage by males compared to females.31  6 
Furthermore, studies indicate a 3 – 11% use in US high school students, 4 – 12 % in US male 7 
adolescents and up to 2% in young US women,32 and use by around 3% of young males in many 8 
‘western’ countries,33 with their use being more prevalent amongst body builders and weightlifters 9 
(3 – 5%).33  AAS use has even been reported in younger age groups such as adolescent boys 10 
(1.7%) and girls (1.4%); as well as pre-adolescents where the prevalence was 1.2 – 3.0%.35 At 11 
the other end of the age spectrum, the therapeutic prescription of AAS and related anabolic 12 
agents have the potential to benefit older adults through their anti-ageing properties, such as the 13 
prevention of sarcopaenia and, as a consequence, they are also taken illicitly by some adults 14 
without medical supervision for their perceived physical enhancement.30  15 
 16 
The illicit access to these drugs by both those involved in competitive sport and those seeking 17 
physical enhancement for aesthetic reasons appears to be through a combination of: physicians, 18 
pharmacies (both with and without the required prescription), fellow gym users, external suppliers 19 
and the internet.24 Indeed some studies indicate that more than 50% of AAS users in some 20 
groups acquire their drugs through physicians.24   21 
 22 
It is also interesting to note that a number of studies have reported an association between the 23 
use of sport performance/physique enhancing doping agents and other risk behaviours, such as 24 
increased alcohol intake and use of recreational drugs such as cannabis and cocaine.36 25 
Additionally, other studies have found an increased likelihood of adolescents using AAS to smoke, 26 
shared needles, possess a weapon, and exhibit suicidal behaviour, all of which result in further 27 
health risks.37 28 
 29 
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Review of doping categories: their effects on physique, performance and health 1 
 2 
S1 – Anabolic Agents 3 
This category includes: Anabolic Androgenic Steroids (AAS) and other Anabolic Agents such as 4 
selective androgen receptor modulators (SARMs). 5 
 6 
Anabolic Androgenic Steroids (AAS) 7 
Anabolic and ergogenic properties 8 
AAS are synthetic derivatives of the hormone testosterone, which is also included in this category 9 
and is the most prevalent AAS. Other commonly used AAS include: nandrolone decanoate, 10 
methandienone, stanozolol, androsterone, and androstane.38 AAS are primarily used to increase 11 
muscle mass and as a consequence are associated with activities that require strength and high 12 
levels of peak power, such as weight lifting, throwing events and sprinting.  They are also used by 13 
those seeking to increase muscle mass per se, which includes those seeking to attain a greater 14 
musculature and physical presence, as well as competitive body builders.  Additionally. their use 15 
is known to extend to endurance athletes and cyclists who use AAS in smaller doses to increase 16 
red blood cell mass and haematocrit, which may augment oxygen delivery and utilisation, as well 17 
as aiding recovery.39  Furthermore, the reported psychotrophic effects of AAS include the 18 
elevation of mood, determination and aggression, all of which may aid in training and competition, 19 
but may result in psychological health problems as well as inappropriate and undesirable 20 
behaviour in social as well as sporting contexts.40 21 
 22 
The anabolic properties of AAS promote increases in muscle mass and aid recovery, whilst the 23 
androgenic properties promote masculinisation, which has particular health implications when 24 
taken by females due to their virilising effects.  The production of endogenous testosterone is 20 – 25 
30 times higher in males than females, which results in males having around a ten-fold greater 26 
blood testosterone level.40 Hence it could be suggested that in terms of gains in muscle mass and 27 
strength, women have the capacity to gain a greater relative increase from AAS use than men: a 28 
feature that was evidently exploited in the GDR doping program. 29 
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 1 
AAS may be taken orally, via intra-muscular injections or through topical gels and creams.  The 2 
use of AAS as a doping agent involves doses that are considerably greater than those prescribed 3 
medically for therapeutic purposes, which has implications for research studies in which the use of 4 
therapeutic doses are unlikely to produce the performance benefits of the supraphysiological 5 
doses taken by athletes.30  Hence many early studies failed to detect performance benefits, 6 
whereas more recent studies using supraphysiological doses provide evidence for their effects in 7 
enhancing muscle mass and strength. 8 
 9 
As previously indicated, AAS are used by individuals seeking to become more muscular for 10 
aesthetic rather than sport performance goals and here their potential effectiveness is 11 
unequivocal.41 However, whilst increases in muscle strength and aerobic capacity are evident, 12 
what is less certain is the extent to which these translate into improvements in performance, but 13 
the lack of unequivocal evidence  may be due to the ethical and research design issues 14 
associated with undertaking double-blind clinical trials of a banned substance on competitive 15 
sportsmen and women.40  Indeed, the prevalence of AAS use in these groups, despite their use 16 
being banned and the reported health risks, would suggest a belief in their effectiveness amongst 17 
elite sportsmen and women.   18 
 19 
Health risks 20 
As indicated above, doping practices use doses of AAS that are considerably greater than those 21 
prescribed therapeutically, consequently many of the elevated health issues associated with 22 
doping are due to these supraphysiological intakes.  Anabolic androgenic steroids use has been 23 
associated with adverse effects upon the cardiovascular system, liver, kidney, endocrinological 24 
and reproductive systems.  The cardiovascular health issues include: elevated concentrations of 25 
low density lipoprotein cholesterol (LDL-C) and lower concentrations of high density lipoprotein 26 
cholesterol (HDL-C); increased triglyceride levels,30, 33, 42-44 elevated systolic and diastolic blood 27 
pressure,42, 43 which is reported in some studies but not others;45 endothelial dysfunction;46 28 
increased concentration of clotting factors, thrombosis,47 hyperinsulinaemia and reduced glucose 29 
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tolerance;30, 43, 47 left ventricular hypertrophy, 42, 43 cardiomyopathies,30, 33 fibrosis and 1 
myocytolysis,48 and polycythaemia.49  Right as well as left ventricular function may be impaired, 2 
including slower diastolic velocities,50 and there are reported cases of acute myocardial infarction 3 
and non-fatal and fatal ventricular arrhythmias.30, 42, 48, 49  51  These aforementioned changes, which 4 
represent an increased risk of atherosclerosis and other cardiac pathologies may be evident for 5 
some time after AAS use has been discontinued and damage to vital organs may be 6 
permanent.23, 42, 45 7 
 8 
AAS use is also associated with alterations to liver function, cholestatic jaundice, peliosis hepatis, 9 
hepatocellular hyperplasia and hepatocellular adenomas, with these changes being linked to the 10 
use of orally taken 17 α-alkylated AAS.30, 44 Additionally there are reported increased risks of liver 11 
tumours with the death from hepatic carcinomas of some athletes being linked to AAS use.44, 52 12 
Similarly renal dysfunction and Wilms tumours have been reported in athletes using AAS.44, 53 13 
 
14 
The adverse effects on the male reproductive system relate to the effects of exogenous AAS 15 
suppressing the hypothalamic-pituitary-testicular axis (HPT) and reducing the levels of the 16 
gonadotrophic hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which 17 
ultimately reduces the levels of circulating endogenous testosterone.43  There is also a reduction 18 
in sex hormone-binding globulin (SHBG).30  These endocrine changes are associated with 19 
reductions in testicular size, sperm count, sperm motility and changes to sperm morphology.30, 44, 20 
54  However, in many cases these changes appear to be reversible upon cessation of AAS use.33  21 
In males there are also reports of prostatic hypertrophy,55 and AAS use is also associated with 22 
gynecomastia, due to the peripheral conversion of androgens to estradiol and estrone.44  Indeed 23 
anti-estrogenic drugs are taken by some AAS users to ameliorate this effect.55 24 
 25 
In females AAS use can result in menstrual abnormalities and virilisation, such as: deepening of 26 
the voice, breast shrinkage, male-pattern baldness, increased libido, acne, body hair, and an 27 
increase in the size of the clitoris, with some of these changes not being reversible.30, 44 28 
 29 
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Other effects in both men and women include the androgenic stimulation of the sebaceous 1 
glands, resulting in acne, which can be severe, affecting the face, back, shoulders and chest.44, 56 2 
Additionally, there have been reports of spontaneous subdural haematomas in weight lifters using 3 
AAS, which may have caused vascular changes that made the individuals vulnerable to these 4 
events when performing the valsalva manoeuvres whilst lifting.57 Other physical consequences of 5 
AAS use may include an increased risk of tendon injuries, as some researchers suggest that the 6 
muscles may increase in strength disproportionately to the tendons, which then become 7 
vulnerable.44 Case studies have also reported that AAS use in adolescents may cause premature 8 
epiphyseal closure of the growth plates in the long-bones thereby preventing full stature being 9 
attained.30.44 10 
 11 
Furthermore AAS use has been associated with adverse mental health, including aggressive 12 
behaviour, commonly referred to as ‘roid rage’,44,58 and prior use of AAS has been associated with 13 
a 2 to 4 fold increased risk of suicide in former athletes.59 Other studies have suggested a link 14 
between the use of AAS and other health behaviours, such as high alcohol intake and the use of 15 
illicit recreational drugs.60  16 
 17 
Clinical implications 18 
With the aforementioned health effects come changes to routine diagnostic laboratory test results, 19 
i.e. medical testing conducted outside of the WADA testing laboratory.  As the prevalence of AAS 20 
use is thought to be high, embracing all levels of sport, it is likely that a proportion of pathologies 21 
seen in laboratory test results could be linked to AAS use.  The clinical interpretation of laboratory 22 
test results is essentially about pattern recognition and Table 3 is provided to highlight potential 23 
analytes that may be altered in association with doping, in particular AAS.  In addition, Figure 2 24 
provides the relationship of the endogenous steroid hormones and their metabolites measured in 25 
various clinical diagnostic settings.61 26 
As part of the differential diagnosis, abnormal hormone patterns observed in laboratory test 27 
results should include consideration of AAS administration.  Case examples highlighting the 28 
pattern of low testosterone with decreased LH levels demonstrate the difficulties faced with the 29 
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interpretation of results, as exemplified in Table 4.62,63 After exclusion of other causes, even when 1 
a patient emphatically denies taking AAS, consideration should be given to the patient unwittingly 2 
taking substances as part of other apparently non-hormonal nutritional supplements.  This is a 3 
valid consideration as up to 15% of “non-hormonal” nutritional supplements have been found to 4 
contain varying concentrations of anabolic steroids purportedly through cross contamination 5 
during the production process.64   6 
 7 
Other Anabolic Agents  8 
Other anabolic agents include Dehydroepiandrosterone (DHEA), which is secreted by the adrenal 9 
glands and is a precursor to testosterone.  Whilst it is reported to be taken by individuals seeking 10 
to enhance their muscle mass, research studies on its effectiveness in male athletes are 11 
equivocal.  It is also taken for its suggested anti-aging and anti-obesity properties, but again its 12 
effectiveness remains unclear.30 In women it appears to increase the circulating concentrations of 13 
testosterone and thereby increase the health issues associated with virilisation, including acne 14 
and hirsuitism, as well as reducing HDL-C, insulin sensitivity and glucose tolerance,30 which have 15 
implications for increased risk of Type 2 diabetes.  Through its influence on the concentration of 16 
circulating testosterone, the health risks associated with DHEA are accordingly those stated 17 
above for AAS.55 18 
 19 
Selective Androgen Receptor Modulators (SARMs) are drugs that may be taken to enhance the 20 
action of the testosterone receptor,43-45 and thereby attain a greater anabolic effect.  Clinical trial 21 
reports related to non-steroidal selective androgen receptors suggest that they are likely to induce 22 
the desired anabolic effects of circulating anabolic hormones, whilst minimising the often 23 
unwanted androgenic effects that present with AAS, such as the virilisation of women and 24 
feminisation of men.65 To date the health issues associated with their use remain unclear. 25 
However, it is suggested that if they are taken without AAS, the individual may gain some 26 
hypertrophic benefits to the muscles, without incurring the aforementioned health risks associated 27 
with AAS use. This would be a result of the SARMs acting on the receptors within muscle and 28 
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bone, but not affecting other organs such as the prostate or virilising other tissues.23 Clenbuterol 1 
is another anabolic agent, but is discussed under the category of beta 2 agonists. 2 
 3 
S2 – Peptide Hormones, Growth factors and Related Substances 4 
This category includes:  5 
(i) Erythropoiesis-stimulating agents, such EPO; 6 
(ii) Chorionic Gonadotrophin (CG) and LH and their releasing factors in males; 7 
(iii) Corticotrophins and their releasing factors; and  8 
(iv) Various growth factors, including but not limited to hGH and its releasing factors and 9 
IGF-1. 10 
 11 
Erythropoietin (EPO) 12 
EPO is a glycoprotein hormone that is produced endogenously by the kidney and to a lesser 13 
extent (<10%) by the liver.66 Its function is to promote the production of erythrocytes 14 
(erythropoiesis).  Under normal aerobic exercise conditions, transient hypoxia is detected by cells 15 
within the kidney and liver, with a resultant increase in EPO production.  This stimulates the 16 
proliferation and differentiation of erythroid precursor cells in the bone marrow and results in the 17 
post-exercise generation of additional erythrocytes.23 In turn, this enhances the capacity to deliver 18 
oxygen to the exercising muscles in subsequent exercise sessions.  With recombinant EPO 19 
(rhEPO) being developed and becoming available in recent decades this training effect can be 20 
augmented pharmacologically, resulting in even greater red blood cell production and 21 
haemoglobin mass. 22 
The detection of rhEPO use has been problematic, with both endogenous and rhEPO having the 23 
same amino acid sequence.  However in some versions of rhEPO there are small differences in 24 
the side chains with rhEPO exhibiting fewer sialic acid residues due to glycosylation, although the 25 
recent increase and widespread production of rhEPO has resulted in other variations which 26 
further complicate the detection process.67  Recent developments in anti-doping strategies now 27 
include an athlete’s ‘Biological Passport’.  This requires a record to be kept of the results of 28 
several blood samples and new samples to be compared against the athlete’s historical record.  29 
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Experts evaluate the records to determine whether any changes to the athlete’s blood profile 1 
suggest doping.  Those with suspicious profiles can then be targeted for additional testing by the 2 
anti-doping agencies.67-69 Other doping methods that have the potential to enhance oxygen 3 
delivery to the muscles are covered in section M1. 4 
 5 
Ergogenic properties 6 
Clinical studies with trained athletes have shown rhEPO to increase haemoglobin mass from 12.7 7 
±1.2 g/Kg to 15.2 ± 1.5 g/Kg.70  This increases the capacity to utilise oxygen (VO2 max) by around 8 
5 – 10% and reduce the time to run 3000 metres by approximately 6%.70,71  Perhaps the most 9 
infamous use of rhEPO has been in the Tour de France, with several prominent cyclists later 10 
confessing to using rhEPO 72 and subsequent revelations about rhEPO use by seven times Tour 11 
de France winner Lance Armstrong are well publicised.73  The endemic use of EPO in cycling 12 
events is supported by the experiences of elite cyclist Tyler Hamilton 74 and whilst some individual 13 
riders had been withdrawn or suspended from the race in previous years its systematic use by 14 
teams was revealed in 1998 tour when one team was ejected from the race for using EPO and six 15 
other teams quit the event.75  Other sports in which rhEPO use have been implicated include 16 
endurance running and endurance events in the Winter Olympics.23 17 
 18 
Health issues 19 
The use of rhEPO results in an increase in red blood cell mass that is greater than an increase in 20 
the plasma volume, hence the blood becomes more viscous,76 and studies have demonstrated 21 
haematocrit increasing from 42.7 ± 1.6% to 50.8 ± 2.0%.71  Notably an haematocrit >50% has 22 
been used in some sports, such as cycling, as a threshold, above which the individual is not 23 
permitted to participate, the inference being that they may have doped.67  From a health 24 
perspective the increased blood viscosity is believed to increase the risk of thrombosis, which 25 
may be further elevated if the person becomes dehydrated.52 Indeed some authorities have 26 
implicated rhEPO abuse with the death of competitive cyclists and other endurance athletes,55 27 
although the association does not appear to have been proven unequivocally.77  Other reported 28 
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health risks include: hypertension and headaches,22 and some authorities suggest that rhEPO use 1 
may be associated with the development of some cancers.52  2 
 3 
hCG and hLH in males 4 
In males, endogenous hCG and hLH act on the Leydig cells of the testes to stimulate testosterone 5 
production.78 Because of this action, hCG and hLH and their recombinant versions (rhCG and 6 
rhLH), have the potential to be used as doping agents by males to promote the body’s own 7 
production of testosterone and epitestosterone.  The use of hCG/rhCG and hLH/rhLH in this way 8 
may thereby circumvent the risks of detection associated with using exogenous testosterone 9 
since both testosterone (T) and epi-testosterone (ET) are increased.  This helps to maintain the 10 
normally occurring ratio of T/ET at around 1 - 2 and avoids the problem of a T/ET ratio exceeding 11 
six, which can occur when exogenous testosterone is used 79 and such test results initiate further 12 
investigations.23, 80  However, whilst a high T/ET ratio is used as an indicator of a possible doping 13 
offence by anti-doping authorities, it is acknowledged that some individuals have naturally 14 
occurring low levels of epi-testosterone which result in an elevated ratio.81  Alternative tests 15 
involve assessing the T/LH ratio on the basis that the use of AAS suppresses LH production and 16 
thereby elevates the T/LH ratio.81,82  Recombinant hCG may also be taken by males to restore 17 
endogeonous T production by the testes, which may be suppressed through the use of 18 
exogenous AAS.83  In males hCG/rhCG and hLH/rhLH concentrations above certain levels 19 
suggest a possible doping violation, however it is also known that hCG can become elevated in 20 
cases of testicular cancer.39,83  Indeed there have been occasions when a doping test has 21 
resulted in tumours being identified in athletes who were unaware of their condition.84 22 
 23 
In females, endogenous hCG and hLH stimulate progesterone and estradiol production by the 24 
ovaries.  Endogenous hCG increases in pregnancy and the hLH surge in the menstrual cycle 25 
triggers ovulation. Consequently these hormones have different levels and functions for males 26 
and females.  In females hCG/rhCG is not believed to substantially alter T levels.23 Therefore, for 27 
this and the previously indicated confounding reasons, which include an intrusion of privacy, 28 
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neither hCG/rhCG nor hLH/rhLH are believed to be effective as doping agents in females nor are 1 
they systematically tested for.85 2 
 3 
Corticotrophins 4 
These are hormones secreted from the anterior pituitary gland that act on the adrenal cortex to 5 
influence the secretion of various hormones.  The key hormone is Adrenocorticotrophic hormone 6 
(ACTH) and its primary function is to promote the release of corticosteroids such as cortisol (see 7 
section S9).  The performance effects of corticotrophins are equivocal.86 8 
 9 
hGH and IGF-1 10 
Human Growth Hormone is a polypeptide hormone that affects many metabolic activities within 11 
the body, notably the growth and division of cells.  Endogenously it is secreted in a pulsatile 12 
pattern from the anterior pituitary whilst exogenous sources include synthetic recombinant Growth 13 
Hormone (rhGH), which is difficult to distinguish from endogenous sources.  Endogenous 14 
production of hGH has been shown to increase in response to high intensity aerobic exercise.87 15 
Some of the indirect effects of hGH are mediated IGF-1, which is produced in the liver and up-16 
regulated by hGH.  Among its numerous effects, IGF-1 promotes amino acid uptake and protein 17 
synthesis in muscles, which makes it an anabolic agent increasing muscle mass and strength.23 18 
However in contrast to hGH, it can cause hypoglycaemia and does not appear to be lipolytic.88 19 
Unlike the pulsatile release of hGH levels, IGF-1 serum concentrations are less variable across a 20 
day.23 21 
 22 
Anabolic and ergogenic properties 23 
Medically, exogenous hGH (including rhGH) promotes muscle growth in people with growth 24 
hormone deficiency (GHD).  This has led to its use as an anabolic doping agent by bodybuilders, 25 
weightlifters and people involved in sports requiring high levels of strength and power.89 It is also 26 
taken for its lipolytic effects that facilitate the loss of body fat, which also makes it attractive to 27 
body builders.  However the extent to which the increases in muscle mass translate into improved 28 
sports performance are unclear.23,88,90-92 Some authorities question whether there is strong 29 
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evidence for its effectiveness if taken as a sole doping agent by those who are not GHD, although 1 
they do suggest that it could have a synergistic effect if taken in combination with AAS.93  As with 2 
studies on AAS, clinical studies with hGH may use lower doses than those taken by sports 3 
performers and hence may not provide a true reflection of its ergogenic potential.91  The use of 4 
rhGH to benefit aerobic/endurance exercise lies in its potential to enhance lipolysis and thereby 5 
spare muscle glycogen, which is a limiting factor in prolonged (>2h) exercise.94  However, despite 6 
the equivocal nature of the clinical evidence, hGH is being used by athletes across a range of 7 
sports events from the 100m sprint to the Tour de France; and the conviction of Sylvester Stallone 8 
for possession of hGH when entering Australia would suggest that its use extends beyond the 9 
sporting arena.95 10 
 11 
Health issues 12 
The use of hGH in supra-physiological doses, which in athletes may be ten times higher than the 13 
therapeutic dose,95 is known to cause fluid retention due to its effects on increased sodium 14 
retention by the kidneys, with peripheral oedema resulting in swollen hands and feet as well as 15 
headaches and hypertension.  It may also cause carpal tunnel syndrome and long term use can 16 
produce aspects of acromegaly54 (the abnormal growth of the bones) which occurs in those with 17 
inherently elevated levels of hGH.  Additionally, since acromegaly is associated with muscle 18 
weakness it has been argued that it could theoretically have an adverse effect on performance,52 19 
although its widespread use by power athletes and bodybuilders would suggest otherwise.23   20 
 21 
Human Growth Hormone abuse has also been reported to increase the risk of cardiomyopathy, 22 
possible arrhythmias, insulin resistance that can lead to diabetes mellitus, bone abnormalities, 23 
adverse lipid profiles, acute renal failure and osteoarthritis.23,52,55,96  As a doping agent it can be 24 
obtained as synthetically produced recombinant human growth hormone (rhGH), but has also 25 
been available from cadaveric sources, which incur the risk of contracting Creutzfeldt-Jacobs 26 
disease.93,95   27 
 28 
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Some studies report the adverse effects of IGF-1 to be hypoglycaemia, myalgia and fluid 1 
retention,97 whilst others indicate that the long term effects of its abuse are largely unknown.98 2 
Growth hormone and IGF-1 abuse have also been associated with colon, breast and prostate 3 
cancers.52,77 4 
 5 
S3 - Beta 2 agonists 6 
Adrenaline and noradrenaline are catecholamine hormones that are released from the adrenal 7 
medulla and also function as neurotransmitters.  Their secretion increases at times of stress and 8 
facilitates a physiological response to a situation.  In a sporting context this relates to increases in 9 
cardiac output, vasodilation, ventilation and circulating glucose, with the response being 10 
proportional to the intensity of the exercise.  These catecholamines bring about their effects 11 
through binding to ß-adrenoceptors (ß-AR), both ß1-AR and ß2-AR.
99  These ergogenic properties 12 
have been exploited by the use of doping agents in the classes of ‘beta 2 agonists’ and 13 
‘stimulants’ (see section S6). 14 
 15 
Beta 2 agonist drugs that have the potential to be doping agents in sport focus on the ß2-AR in the 16 
brain and peripheral tissues.  Stimulation of these receptors result in  diverse effects such as, 17 
bronchodilation, anabolic actions and the enhancement of anti-inflammatory corticosteroids.99 18 
Beta 2 agonist drugs may be inhaled or taken orally and are commonly used as medications to 19 
treat and prevent asthma.  WADA prohibits the use of beta 2 agonists, including bronchodilators 20 
unless the participant has a ‘therapeutic exemption’, which must be applied for.100 This exception 21 
covers a limited list of drugs such as formoterol, salbutamol, salmeterol and terbutaline when 22 
taken via inhalation.  Studies suggest that these drugs do not appear to have an ergogenic benefit 23 
when inhaled, but salbutamol may improve strength and endurance if taken orally.101 One beta 2 24 
agonist that has been used as a doping agent in sport is clenbuterol.  Clenbuterol is a non-25 
steroidal anabolic agent that increases muscle mass, which would explain its use by weightlifters 26 
and other strength athletes.  It is also used in the livestock industry and some recent reports 27 
suggest that eating the meat of animals given clenbuterol could result in a positive test.102 28 
 29 
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Ergogenic effects 1 
In terms of performance benefit for the elite non-asthmatic athlete ß2- agonists do not improve 2 
aerobic capacity (VO2 max), performance in endurance events or peak cycling power.
103  Similar 3 
results were found by Elers and colleagues who also found no effect on oxygen kinetics.104  4 
However Pluim et al.’s analyses of studies that had used systemic ß2- agonists produced 5 
equivocal results, with some studies indicating that they could benefit endurance performance and 6 
cycling sprint power, and others concluding that oral ß2- agonists, combined with resistance 7 
training could improve strength.103,105  Hence the therapeutic inhaled doses of ß2- agonists do not 8 
appear to be ergogenic, but systemic and supra-physiological doses may enhance the effects of 9 
strength training and benefit endurance performance. 10 
 11 
Health risks 12 
Clenbuterol and salbutamol are the most commonly reported doping agents in this class, with 13 
clenbuterol in particular being taken for its anabolic properties. Since beta 2-AR agonist drugs 14 
bind to the ß2-AR in the heart they thereby elicit health risks such as cardiac arrhythmias, 15 
palpitations and myocardial ischemia.106 They are also reported to cause muscle tremor and may 16 
increase circulating glucose concentrations due to their action on the liver.  Additionally 17 
clenbuterol has also been associated with reducing bone mineral content.91 18 
 19 
S4 – Hormone and Metabolic Modulators 20 
The prohibited list divides this category into five groups:2 21 
(i) Aromatase inhibitors 22 
(ii) Selective estrogen receptor modulators (SERMs) 23 
(iii) Other anti-estrogenic substances 24 
(iv) Agents modifying myostatin function(s) 25 
(v) Metabolic modulators 26 
 27 
Aromatase inhibitors, selective oestrogen receptor modulators (SERMs) and other anti-28 
estrogenic substances 29 
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These drugs are used clinically in the treatment of breast cancer or other tumours that are 1 
hormone dependent.  They are also used in the treatment of osteoporosis.  In males oestradiol is 2 
produced by the aromatization of testosterone and this oestradiol plays a key role in the negative 3 
feedback regulation of testosterone production via the hypothalamic-pituitary-testicular axis.  4 
Oestrogen blocker drugs include anti-oestrogen drugs that block oestrogen receptor action and 5 
aromatase inhibitors that block the synthesis of oestradiol.  Hence when males take these drugs 6 
the negative feedback process is interfered with, resulting in increased secretion of 7 
gonadotrophins from the pituitary and a subsequent increase in circulating testosterone.40 They 8 
may therefore convey an ergogenic benefit to men from the elevated levels of testosterone. 9 
Additionally, they may be taken by men trying to prevent the development of gynecomastia, which 10 
occurs with AAS abuse that results in elevated oestrogens.23 Due to the physiological and 11 
endocrinological differences between men and women, oestrogen blocker drugs are unlikely to 12 
increase testosterone levels in women to levels that would measurably increase muscle mass or 13 
strength. When used inappropriately the health risks include cardiac arrhythmias, dizziness, 14 
osteoporosis and joint pain.  Some can also result in breathlessness. 15 
 16 
Agents modifying myostatin function(s) 17 
Myostatin (growth differentiation factor 8 (GF-8)) is a naturally occurring hormone that regulates 18 
muscle growth. Its function is to limit growth and hence muscle mass.  Naturally occurring genetic 19 
mutations occur in which the myostatin is non-functional and this results in an abnormally large 20 
muscle mass, with homozygous conditions being more extreme than the heterozygous condition.  21 
This is exploited in the livestock industry with the Belgian Blue and Piedmontese cattle breeds in 22 
which abnormalities in the myostatin genes result in cattle with greater muscle mass and hence 23 
increased meat production.  Further examples occur in greyhounds and there are a few recorded 24 
examples in humans.  Clinically, myostatin inhibitors endeavour to inhibit the normal action of 25 
myostatin and thereby have the potential to treat muscle wasting conditions such as sarcopaenia, 26 
muscular dystrophy and cancer cachexias.23 As doping agents this inhibitory effect may enable 27 
muscle hypertrophy to exceed that attainable under non-doping conditions. 28 
 29 
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Metabolic modulators 1 
Metabolic modulators include insulins, and Peroxisome Proliferator Activated Receptor δ (PPAR 2 
δ) agonists.  Insulin is a key regulator of glucose levels within the blood, and is secreted by the β 3 
cells of the pancreas primarily in response to high blood glucose concentrations.  Clinically, it is 4 
used by insulin dependent diabetics whose endogenous production of insulin is insufficient or 5 
non-existent.  The use of exogenous insulin by non-diabetics can lower blood glucose to 6 
hypoglycemic levels, resulting in the risk of dizziness and coma in more extreme cases.  As a 7 
doping agent, insulins may increase the rate of glucose uptake into the muscles and thereby aid 8 
recovery by facilitating muscle glycogen replenishment. In addition to their hypoglycemic 9 
properties, insulins have an anabolic action, which makes them potential doping agents for 10 
increasing muscle mass.23,107  However, whilst there are some reports of insulin abuse it does not 11 
appear to be as widespread as other anabolic agents. 12 
 13 
Peroxisome Proliferator Activated Receptor δ (PPAR δ) agonists specifically mentioned in the 14 
WADA prohibited list are 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR; 15 
peroxisome proliferator–activated receptor-δ [PPAR-δ]-AMPK agonist) and GW1516 (PPARδ-16 
agonist).2  Their inclusion on the prohibited list relates to their effect in augmenting the 17 
adaptations to endurance training, such as the enhancement of mitochondrial biogenesis, 18 
angiogenesis and insulin sensitivity108 , with the overall outcome being muscle fibres with a 19 
greater aerobic capacity and greater fatigue resistance.  Mechanistically PPARδ are believed to 20 
be involved with AMPK and PGC-1α responses, which have well established roles in the 21 
promotion of biogenesis post-exercise. 22 
 23 
Health risks 24 
As mentioned previously, one of the consequences of AAS abuse is their conversion to 25 
oestrogens, with a resultant risk of gynaecomastia.  To combat this, oestrogen anatagonists such 26 
as SERMS may be used, as are aromatase inhibitors that inhibit the synthesis of oestrogen.  The 27 
health risks associated with the specific use of these drugs as doping agents by ‘healthy’ 28 
individuals is currently unclear, since they are taken in combination with other doping agents.  29 
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However it is suggested that oestrogen blocking agents and aromatase inhibitors do not have 1 
direct androgenic effects, and therefore do not convey the health risks associated with the use of 2 
androgens such as AAS.40 The health risks associated with the use of myostatin inhibitors are 3 
likewise unclear at this stage, but their potential for development as therapeutic agents means 4 
that their use may become more widespread in the future. 5 
 6 
S5 -  Masking Agents 7 
Masking agents are not considered performance-enhancing, but they are taken to conceal the use 8 
of other doping agents and abuses.  They include diuretics, epi-testosterone, probenecid, 5α-9 
reductase inhibitors and plasma expanders.  The mechanism of action varies, with the intention 10 
being to reduce the concentration of the doping agent or its metabolites in the sample through 11 
increasing the volume of urine or reducing the rate of excretion of the doping agent/metabolites 12 
into the urine; or alternatively by interfering with the parameters used by anti-doping labs to 13 
identify doping offences.109 14 
 15 
Diuretics 16 
Therapeutically, diuretics are used to increase urine production and sodium excretion.  They are 17 
prescribed for a variety of conditions, such as hypertension, heart failure, liver, kidney and lung 18 
diseases.110 Diuretics promote urine production.  As doping agents they are used in a number of 19 
sporting context for a variety of reasons, with the 2008 WADA laboratory statistics indicating that 20 
nearly 8% of positive samples involved diuretics.111 The diuretic induced increase in urine 21 
production has two effects that may be exploited by the doping athlete.  Firstly it can produce a 22 
rapid and temporary weight reduction when endeavouring to make a weight category in sports 23 
such as boxing.  It may also be used to counteract fluid retention, which can occur when using 24 
other drugs, notably in body building where the fluid excess would conceal the definition of the 25 
musculature.  Secondly the increased urine volume will lower the concentration of doping agents 26 
and/or their metabolites in a urine sample, with the intent of reducing the concentration to below 27 
detectable levels.  Thirdly, some diuretics can alter urinary pH and inhibit the excretion of some 28 
drugs into the urine, thereby lowering their concentration in urine samples.110 29 
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 1 
Health risks 2 
The use of diuretics either to reduce weight or mask the use of other doping agents through the 3 
production of copious amounts of dilute urine, entails the risk of dehydration and excessive loss of 4 
minerals such as potassium and calcium. 5 
 6 
Probenecid 7 
Therapeutically, probenicid is used to treat chromic gout and may also be prescribed alongside 8 
antibiotics for the treatment of some bacterial infections. Probenecid acts on the renal tubules of 9 
the kidneys to increase the excretion of uric acid and reduce the excretion of some acidic 10 
compounds..  In a doping context this would include a reduced excretion of testosterone, epi-11 
testosterone and AAS, which are excreted mainly as their glucuronic acid compounds. In such 12 
contexts the purpose of using probenecid is to lower the concentrations of exogenous doping 13 
agents and their metabolites to below the detectable levels.109 It may also interfere with the levels 14 
of endogenous T and E in urine samples. 15 
 16 
Plasma expanders 17 
Clinically, plasma expanders, in the form of colloid solutions containing dextrans, are used in 18 
situations of blood or fluid loss.  As doping agents they may be used to mask the use of EPO and 19 
blood infusions.  The rationale for their use is that EPO and blood infusions will increase the 20 
haematocrit and Hb levels, which are advantageous in endurance sports.  Sports authorities set 21 
thresholds for haematocritand the concentration of haemoglobin, above which  a possible EPO 22 
and/or blood transfusion doping offence is indicated.  Plasma expanders will temporarily dilute the 23 
blood,  lowering the haematocrit and Hb concentration, thereby bringing them below the levels 24 
that are used as indicators of doping. 25 
 26 
M1 – Manipulation of Blood and Blood Components  27 
 Autologous and allogenic Blood Doping 28 
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As previously stated, increasing RBC elevates the capacity of the body to deliver oxygen to the 1 
exercising muscles and increases aerobic performance.112,113  Key to this improvement is the 2 
increase in the total Hb mass rather than [Hb] or Hct, although these tend to increase alongside 3 
the increase in Hb mass.114,115  Consequently drugs such as rhEPO are banned (see section S2).  4 
Prior to the availability of rhEPO in the 1980s, endurance athletes and cyclists are known to have 5 
achieved an increase in RBC via the transfusion of matched blood from another person 6 
(homologous or allogenic blood doping) or through the reinfusion of their own blood, which had 7 
been removed around 4 weeks previously and then reinfused 1 – 7 days before the event 8 
(autologous blood doping).  Since the development of tests to detect rhEPO and allogenic blood 9 
doping in the early 2000s,113 autologous blood transfusion has made a resurgence amongst those 10 
wishing to avoid detection.116  Tests to detect autologous doping assess inconsistencies in the 11 
blood profile of athletes in accordance with the Athlete’s Biological Passport, in which a record of 12 
their blood profile from previous tests has been recorded.  Longitudinal comparisons of the 13 
athlete’s blood involve assessing a combination of hematologic markers.117  These tests work on 14 
the basis of detecting altered erythropoiesis and include  measures of total mass of haemoglobin 15 
and the ratio between the amount of Hb in the mature erythrocyte population and the reticulocytes 16 
(RBCHb:RetHb ratio).116,118,119  Other suggested markers relate to the body’s response to the 17 
withdrawal of blood (anaemic phase) in which [Hb] is reduced, whilst EPO, % reticulocytes and 18 
sTfR increase for a number of days until the blood loss is replenished.120  Another approach for 19 
the detection of autologous blood doping is to test for markers that indicate that blood has been in 20 
storage.  These include decreases in 2, 3-bisphosphoglycerate, altered cell membrane 21 
structure,112 changes to gene expression related to T lymphocytes that occurs due to a 22 
transfusion induced immune response, and the presence in the urine of metabolites of plasticisers 23 
such as di-ethylexylphthalate (DEHP) that have leaked from the bags in which the blood was 24 
stored.121,122 25 
 26 
Ergogenic properties 27 
A review of early studies conclude that blood doping using 1 – 3 units of blood increased Hct by 28 
up to 13%,  improved aerobic capacity (VO2 max) by 0 – 10% and endurance by 3 – 37%.
123  29 
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These figures were supported by later studies.  In the 1984 Los Angeles Olympics, some 1 
members of US cycling team utilised blood transfusions and achieved exceptional performances 2 
including nine medals; the US having not won a cycling medal in the previous 72 years of the 3 
games.124 The more recent revelations around the Tour de France further support the efficacy of 4 
this practice in enhancing aerobic performance in cycling.74 These doping practises extend into 5 
other sporting arenas, such as distance running and endurance skiing events.121 6 
 7 
Health risks 8 
Health issues relate to the risks of infection and in cases of allogenic blood doping, the risk of 9 
transferred infection and mismatching of blood.   10 
 11 
Artificial enhancement of oxygen uptake, transport and delivery 12 
Other potential agents that enhance oxygen delivery to the muscles include synthetic O2 carriers 13 
such as haemoglobin-based oxygen carriers (HBOCs) and perflurocarbons (PFCs).72,122  14 
However, unlike endogenous Hb, which releases more of its oxygen to the tissues in hypoxic 15 
conditions, the aforementioned exogenous artificial agents do not, which may limit their 16 
effectiveness.  They also have adverse side-effects and may result in tissue damage, which would 17 
not make them conducive as doping agents.72  Likewise, whilst endogenous 2,3-18 
diphosphoglycerate (2, 3 – DPG), which promotes oxygen release to the tissues is clearly 19 
beneficial to the endurance athlete, artificial 2, 3 DPG mimetics do not as yet appear to be 20 
effective in a sporting context due to easy detection and a short half-life.72 However others 21 
suggest that efaproxiral, which alters the haemoglobin-oxygen saturation curve, may be of 22 
benefit.122 23 
 24 
M2 – Chemical and Physical Manipulation 25 
This refers to tampering with a sample taken as part of the anti-doping testing procedures, in 26 
order to alter its integrity and validity.  It also includes the adulteration of samples by the addition 27 
of proteases and other chemicals that alters parameters of the steroid profile, a characteristic that 28 
appears to be relatively consistent within individuals, but is altered by the use of doping agents.  29 
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For the interested reader, aspects of this were investigated and are described in detail by 1 
Kuzhiumparambil and Fu.125 “Intravenous infusions and/or injections of more than 50 mL per 6 2 
hour period except for those legitimately received in the course of hospital admissions or clinical 3 
investigations” are also prohibited.2 4 
 5 
M3 - Gene Doping 6 
The capacity to attain an elite level of performance in sport has a genetic component, and it is 7 
said that to become an elite athlete you need to choose your parents very carefully.  The current 8 
human gene map for performance and health-related fitness phenotypes identifies over 200 9 
genes that appear to be associated with athletic performance:126 some phenotypes favouring 10 
endurance, whilst others favour strength, anaerobic power and sprinting. 11 
 12 
Gene therapy is a concept that has the potential to treat genetically based diseases such as 13 
Cystic Fibrosis,127 Duchenne Muscular Dystrophy and many others.  It works primarily on the 14 
principle of adding a functional gene and/or genetic material into the cells of the recipient and 15 
thereby enabling the expression of a gene.  This may increase the number of copies of the gene 16 
within these cells, or provide a functioning form of the gene to cells when the recipient’s own 17 
genotype includes a less effective or non-functioning mutated version of that gene.  The means by 18 
which this new genetic material gets into the cells is usually via a virus (viral vector) with the virus 19 
being introduced into the body via injection or nasal spray. Once in the target cells the introduced 20 
genetic material will be activated to produce the mRNA and protein that the cell/body currently 21 
lacks.  To date there are relatively few examples of effective gene therapy, but as a concept it has 22 
great potential. 23 
 24 
In a sporting context, the principles of gene therapy have been foreseen as having the potential 25 
for abuse as a doping procedure.  For example, in theory it could be abused to enhance an 26 
athlete’s production of proteins such as EPO,128 hGH and IGF-1,129 vascular endothelial growth 27 
factor (VEGF) and myostatin antagonists that will promote muscle hypertrophy.130 So, whilst there 28 
are no recorded cases of gene doping or even its efficacy in enhancing performance, the 29 
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procedure has been added to the WADA banned list.  Furthermore, the process of gene doping, 1 
which has the potential to temporarily enhance or suppress the production of key proteins could 2 
be further developed into genetic enhancement, whereby the introduced genetic material 3 
becomes fully integrated into that of the recipient and is consequently replicated with the host’s 4 
own genetic material and is thereby be perpetuated with each cell division.  If such procedures 5 
become a reality they may again convey great benefits in a therapeutic setting, but would also be 6 
open to abuse in sport.  For example, as the details of the human genome are further elucidated, 7 
the influence of specific genetic polymorphisms upon the individual’s aerobic capacity and 8 
endurance or ability to produce high anaerobic power and sprint become evident,126  manipulating 9 
the genetic make-up of the individual has the potential to augment their performance. 10 
 11 
In the context of health risks, the science of gene therapy is in its infancy with relatively few 12 
successful clinical trials, but even these have exposed risks with the procedures, and some of 13 
these have fatal consequences, even in carefully regulated clinical trials. 14 
 15 
S6 – Stimulants 16 
Stimulants are a diverse group of banned drugs that are ‘banned in competition’.  They have the 17 
confounding aspect of including drugs that whilst having possible ergogenic properties may also 18 
be found in over the counter medicines and/or be taken as ‘recreational drugs’.  The former would 19 
include ephedrine and pseudoephedrine, whilst the later would include cocaine and ecstasy.  20 
Studies indicate that stimulants account for around 6 – 18% of the positive samples detected in 21 
the sporting context, which makes them the 3rd most prevalent category, behind AAS and 22 
cannabinoids.131 The stimulant caffeine, which is included in a number of sports drinks and gels 23 
and generally consumed broadly around the world, was removed from the WADA banned 24 
substance list in 2004 but is briefly considered in this review.  25 
 26 
The potential ergogenic properties of stimulants primarily relate to their effects on the central 27 
nervous system and their capacity to: reduce the perception of fatigue; increase alertness, 28 
promote self-efficacy and confidence; and in some cases stimulate cardiac output and blood flow 29 
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to the exercising muscles. Typically, they work via their pharmacological effects on increasing the 1 
release of neurotransmitters, blocking the re-uptake of neurotransmitters, and the activation of 2 
receptors. Some mimic the responses of the sympathetic neuroendocrine system, notably 3 
adrenaline and noradrenaline, whilst others affect the dopamine and serotonin systems.132 WADA 4 
list over 60 specific drugs within this category and include a general statement aimed at covering 5 
similar drugs with similar properties. 6 
 7 
Evidence for the ergogenic efficacy of many stimulants on sport performance is often equivocal 8 
and the use of such drugs can entail serious health risksincluding hyperthermia, stroke, 9 
respiratory and cardiac arrest.99 A difficulty with clinical research on the ergogenicity of stimulants 10 
is that the laboratory/experimental setting can rarely, if ever, fully mimic the competition 11 
environment.  As a consequence an enhanced performance in experimental trials, when arousal 12 
may not be maximal, may not translate into the competition environment when the athlete’s 13 
arousal is likely to be higher.  Within this review, a few examples will be mentioned briefly to 14 
illustrate the characteristics of different stimulants.  For a more extensive coverage of the 15 
pharmacological aspects, see the review by Docherty.132 16 
 17 
Amphetamines  18 
Amphetamines may be used in sport to reduce the perception of fatigue and promote 19 
concentration, alertness and self-confidence.  They enhance the brain activity of noradrenaline 20 
and dopamine.133 They also increase blood pressure and peripheral vasoconstriction.   21 
 22 
Health risks 23 
Their use has been associated with ventricular dysrhythmias, increased blood pressure and 24 
peripheral vasoconstriction.76 As a consequence they increase the risk of tachycardia and 25 
cardiovascular failure, as well as reducing the body’s capacity to lose the heat generated during 26 
strenuous exercise, which may result in hyperthermia.134 Some fatalities in endurance cycling 27 
events have been attributed to this, including the televised death of Tommy Simpson in the 1967 28 
Tour de France. Other health risks include anxiety, hallucinations and insomnia. 32,134 Their 29 
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regular use can result in tolerance and dependence that may cause depression following 1 
withdrawal.134   2 
 3 
Sympathomimetics (ephedra alkaloids including ephedrine and pseudoephedrine). 4 
This group includes the drugs ephedrine and pseudoephedrine, which are agonists at both α- and 5 
β-adrenergic receptors, increasing heart rate and blood pressure.135,136  Ephedrine and 6 
pseudoephedrine are sympathomimetics commonly included in decongestant drugs.  WADA 7 
monitor these substances on the basis of a urine concentration threshold due to their presence in 8 
many over the counter medicines, including those for nasal congestion.2  The concentration for 9 
ephedrine is set at >10 micrograms per millilitre and pseudoephedrine is set at >150 micrograms 10 
per millilitre.  Ephedrine acts on the CNS promoting the release of noradrenaline,134 with resultant 11 
increases in heart rate and blood pressure. Other ephedra alkaloids have similar properties and 12 
may be found in traditional Chinese medicines, examples being the herb ma huang or guarana.137 13 
They may be abused by athletes because of a perceived benefit to strength, aerobic performance 14 
and even fat loss, however studies on performance are equivocal, although there is some 15 
evidence that they may convey performance benefits if taken with caffeine.136   16 
 17 
Health issues 18 
Reviews of sympathomimetic drugs indicate that their use has been linked to a number of adverse 19 
cardiovascular events and fatalities, including stroke, arrhythmias and myocardial infarction, as 20 
well as hypertension.134,135 21 
 22 
Cocaine 23 
Cocaine is reported to reduce the perception of fatigue, and promote confidence and euphoria, 24 
which may aid performance. It exerts its effects via the CNS, increasing the release of 25 
catecholamines, dopamine and inhibiting the reuptake of noradrenaline.   26 
 27 
Health risks 28 
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The health risks of cocaine are reported in the wider context of its use as a recreational drug and 1 
include: elevated heart rate and blood pressure, myocardial ischemia, myocardial infarction, 2 
arrhythmias and cardiac arrest even in the absence of atherosclerosis.134,135 It’s considered highly 3 
cardiotoxic when taken with alcohol.134  It can also adversely affect the vascular, pulmonary, 4 
gastrointestinal, musculoskeletal and genitourinary systems, as well as causing cerebrovascular 5 
events.134,138  Additionally, its vasoconstrictive action may adversely affect thermoregulation.76 6 
 7 
Caffeine 8 
Caffeine is a stimulant that is not currently banned by WADA, despite its proven ergogenicity.  In 9 
the past it was included on the banned list at urine concentrations above (12 µg/mL),  on the basis 10 
that concentrations below this level may be attained from the consumption of coffee, coca cola 11 
and similar sources, whereas above this concentration indicated a deliberate consumption, 12 
probably via tablets, with the intent of performance enhancement.  It was removed from the 13 
‘banned list’ in 2004 but is still subject to monitoring, although it should be noted that the 14 
ergogenic benefits for a range of sports appear to be attained at modest doses (3 mg/kg) doses 15 
that are easily achieved via intake of everyday dietary sources such as coffee, cola drinks and 16 
energy drinks.  Indeed, the ergogenic properties of caffeine are broad and evident at relatively low 17 
doses of 3 mg kg-1 body mass.  The performance benefits include: reductions in the perception of 18 
fatigue and direct effects on muscle contractility, although previously claimed mechanisms such 19 
as the promotion of fat as a fuel sources during endurance events is no longer considered 20 
important.139 21 
 22 
S7- Narcotics 23 
The category of narcotics includes substances such as morphine and related compounds. 24 
Morphine is known for its analgesic effects in increasing tolerance to pain, which may thereby 25 
improve performance.  Another notable drug in this category is heroin, the health risks of which 26 
are reviewed elsewhere in the context of its wider use in society. 27 
 28 
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S8 – Cannabinoids 1 
Natural and synthetic cannabinoids are banned ‘in competition’ and there have been a number of 2 
high-profile cases in which athletes have produced positive samples following competition and 3 
been disqualified as a consequence.  Due to their ‘relaxing’ properties, such drugs are likely to 4 
impair performance (ergolytic) rather than being ergogenic.140 but a substance does not have to 5 
have proven ergogenic properties to be included on the WADA banned list, and the cannabinoids 6 
would tend to fall into this realm. Indeed, the reported reasons for taking them include relaxation 7 
and the promotion of sleep prior to competition.  However, due to their effects on alertness, 8 
concentration and reaction time, they may present a safety problem for others as well as the user 9 
in some sporting contexts,141 which is why they are banned. For the wider context, readers are 10 
directed to other reviews on the mental health consequences of taking cannabinoids.142,143 11 
 12 
S9 – Glucocorticosteroids 13 
Physiological glucocorticosteroids include cortisol and cortisone, which have an anti-inflammatory 14 
role.  They are used to treat musculoskeletal and tendon injuries: a common example being 15 
hydrocortisone.  In sport they are ‘banned in competition’ 2 due to their effects on pain relief and 16 
perhaps fatigue, which may aid performance, but may also exacerbate injury to the damaged 17 
tissues as the person is able to continuing loading the tissue in the absence of pain that would 18 
normally cause cessation of the activity.144  In the past they may also have been taken under the 19 
belief that their effects on increasing gluconeogenesis and the mobilisation of amino acids and 20 
fatty acids would aid performance, although the evidence for this is equivocal.145  21 
 22 
Health issues 23 
Glucocorticosteroid injections are sometimes used within the treatment program for Achilles, 24 
quadriceps and hamstring tendons.  However, whilst their use may accelerate the athlete’s return 25 
to training and competition, there is some debate as to whether their use is also associated with 26 
an increased risk of subsequent rupture of the tendon due to degenerative processes and 27 
incomplete repair in the tendon.96,144,146  This has raised concerns about the chronic use of non-28 
steroidal anti-inflammatory drugs, which whilst producing short-term relief may retard complete 29 
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healing and recovery of the tissue.  In addition, the chronic use of glucocorticosteroids may 1 
increase the risk of diabetes mellitus, osteoporosis, necrosis of the femoral head and growth 2 
retardation in children.76,96,147  3 
 4 
 5 
P1 – Alcohol 6 
Within the WADA prohibited substances list alcohol (ethanol) is prohibited in competition in 7 
specific sports above a blood concentration of 0.10 g/L (i.e. 0.01%).2 It is banned for reasons of 8 
safety to the participants and others, in sports including: aeronautics, archery, motorsport, karate 9 
and power-boating.  The acute effects of alcohol consumption are generally ergolytic, but may be 10 
used by the participants in sports requiring ‘boldness’, such as downhill skiing and mountain 11 
biking to overcome inhibitions and thereby improve performance or perception of performance.148 12 
Its health issues will not be discussed here as they are extensively debated elsewhere and in the 13 
wider context of society. 14 
 15 
P2 – Beta-Blockers 16 
Beta-Blockers also come under a category of being prohibited in specific sports during 17 
competition.  Since their effects are antagonistic at the β-adrenergic receptors they have the 18 
effect of slowing the heart rate and reducing blood flow to the muscles, which would be ergolytic 19 
rather than ergogenic.99  However, their performance benefits relate to a calming effect in slowing 20 
the heart rate and reducing tremor, which has been demonstrated to improve pistol shooting and 21 
may benefit similar target sports.149  Hence they are not permitted in archery, motorsport, billiards, 22 
darts, golf, shooting and skiing/snowboarding. The health risks of their abuse include bradycardia, 23 
orthostatic hypotension and arrhythmias, as well as reducing the capacity to thermoregulate.55 24 
 25 
Concluding remarks 26 
In summary, this review has provided an overview of the WADA doping categories, why 27 
substances or methods within these categories are used, the performance benefits, health risks 28 
and implications for clinical samples.  Whilst laboratories accredited by WADA carry out testing for 29 
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these doping agents, in reality novel mechanisms of doping are being utilised by sports people at 1 
all levels to achieve that unfair advantage.  2 
 3 
In the context of health risks, the use of various doping agents, including the most prevalent, such 4 
as AAS, stimulants and EPO, increase the risk of cardiovascular disease, thrombosis, stroke and 5 
cancers in men and women.  Additionally, the use of AAS adversely affect the hormonal axes 6 
resulting in the suppression of endogenous hormone production in males, whilst exerting a 7 
virilising affect in women.  Furthermore the regular use of some anabolic agents and stimulants 8 
can have serious mental health/behavioural consequences.  Hence the physical and mental 9 
health risks associated with the use of such agents are likely to exceed the health benefits 10 
associated with participation in physical activity.  The prevalence of doping agents extends 11 
beyond the realms of elite sport, into lower levels of competition and into non-competitive exercise 12 
training for the development of an enhanced physique.  So whilst the reliability of prevalence data 13 
and health impacts have limitations, the indications are that doping and related drug abuse 14 
represent a significant health issue, and those involved in the clinical testing of samples should be 15 
aware of the potential for some patients sample results to be affected by doping practises. 16 
17 
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Figures and Tables 1 
Table 1: A summary of the world anti-doping agency Anti-Doping Code and Doping 2 
categories. 3 
Substances and Methods Prohibited at All Times 
Prohibited substances: 
S1 – Anabolic Agents 
 Anabolic Androgenic Steroids 
 Other Anabolic Agents 
S2 – Peptide Hormones, Growth factors and Related Substances 
S3 – Beta-2 Agonists 
S4 – Hormone and Metabolic Modulators 
S5 - Diuretics and Other Masking Agents 
 
Prohibited Methods 
M1 – Manipulation of Blood and Blood Components 
M2 – Chemical and Physical Manipulation 
M3 – Gene Doping 
 
Substances and Methods Prohibited In-Competition 
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Prohibited substances: 
S6 – Stimulants 
S7- Narcotics 
S8 – Cannabinoids 
S9 – Glucocorticosteroids 
 
Substances prohibited in Particular Sports 
P1 – Alcohol 
P2 – Beta-Blockers 
S = Substance; M = Methods; P = Particular 1 
2 
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 1 
Table 2: A brief summary of the history of Doping in sport 2 
Year Event 
Second half of 19th Century 
1865 Early report of drug use in sport - Doping by canal swimmers reported in  
Amsterdam 
1800's (last 
third) 
Cyclists of the day are reported to have used coffee 'spiked' with caffeine at the 
start of races and then add increasing doses of cocaine and strychnine to the 
mixture during the races.  Boxers reported to take strychnine tablets with a 
mixture of cocaine and brandy.   
1879 
Six day bicycle race - an 144 hour continuous event.  Various doping agents 
used:  
- caffeine based mixtures (preferred by French racers);  
- sugar cubes dipped in ether (preferred by Belgian cyclists);  
- alcohol-containing cordials; and   
- nitro-glycerine (used specifically by sprinters). 
1886 
DEATH - First fatality attributed to doping reported (unconfirmed).  English 
cyclist, Arthur Linton, was reported to have overdosed on 'tri-methyl' 
(presumably containing caffeine or ether) during a 600km cycling event held in 
France (between Bordeaux and Paris).  Note: Evidence to this report is 
however conflicting with others reporting he died 10 years later. 
1887 Amphetamines first synthesised  
1800's (last 
third) 
Overview of period - The use of stimulants among athletes is common-place 
and not concealed unless the drug combination was unique and thought to 
provide a competitive advantage that the athlete did not want to share.  
First half of 20th Century 
1904 Thomas Hicks, the winner of the marathon in the 1904 St. Louis Olympic 
Games, takes strychnine and brandy several times during the race. 
1928 Doctor, Wilhelm Knoll - a Swiss physician, administers a stimulant (Coramin) to 
skiers at the St. Moritz Olympic Games in 1928 
1932 In the 1932 Los Angeles Olympic Games, the victories of Japanese swimmers 
were rumoured to be the result of their being 'pumped full of oxygen'  
1933 The word doping is now part of the English language 
1935 The first steroid (testosterone) isolated 
1936 Rumours of testosterone injection at the Berlin Olympics among German 
athletes 
mid 1930's 
Amphetamines identified as a central nervous system stimulant and became 
available via prescription in 1937 
late 1940's  
Amphetamines are used for the first time in professional sport 
1945 First evidence of formal discussions about the viability of doping in sport 
through the use of stimulants - Soviet Union 
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1948 
Soviet sport established their goal of meeting or exceeding all world records 
Second half of 20th Century 
1950 Nandrolone (19-nortestosterone) first synthesized by AJ Birch 
1950's - 1960's 
First reports of female anabolic steroid use relates to Soviet female track and 
field athletes 
1954 Soviets employ systematic use of testosterone with their weightlifters 
1956 Growth hormone (hGH) first isolated from the human pituitary gland by Li and 
Papkoff 
1958 
Ciba Pharmaceutical Company released Dianabol (methandrostenolone) and 
US sports doctor Dr. John Ziegler begins experimenting with testosterone for 
the US weight lifting team.  Efficacy of these drugs apparently spread by word 
of mouth during the early 1960s to other strength-intensive sports, from field 
events to football. 
1959 High school sport related drug use rumours to have commenced - a physician 
in Texas allegedly administered Dianabol to the high school football team  
1960 
DEATH: 1960 Rome Olympic Games, Knud Jensen, a 23-year-old Danish 
cyclist, collapsed during competition and dies. Autopsy results revealed the 
presence of amphetamines.  This is the second death in an Olympic 
competition and the first doping related death.  Note: The first Olympic death 
occurred in 1912 at the Stockholm Olympics when a marathon runner died of 
heat exhaustion during the race. 
1961 IOC form a medical committee - in response to the death at the Rome 
Olympics in 1960. 
1960's  Anabolic steroid use became widespread. 
1964 
Urine samples taken from cyclists after the races during the Tokyo Games 
'were actually blue in colour due to the use of various drugs'. 
1965 
Tests conducted on Belgian cyclists in 1965 showed that 37 per cent of 
professionals and 23 per cent of amateurs were using amfetamines, while 
reports from Italy showed that 46 per cent of professional cyclists tested 
positive for doping.  
1966 First clearly documented National doping program commences - GDR doping 
program documented by the STASI. 
1967 
DEATH: First doping death televised.  "29 year old English cyclist (Tom 
Simpson) collapses during the 13th stage of the Tour De France.  The autopsy 
revealed high levels of methamphetamine in his system.  Simpson was 
carrying a vial of methamphetamine on him at the time of his death. 
1967 / 1968 
Doping controls first introduced - at the end of 1967 the International Olympic 
Committee (IOC) votes to adopt a drug-testing policy banning the use of 
specific drugs - not including anabolic steroids.   This policy is released in 
1968.  
1967 
The masculine appearances of a number of female track and field athletes 
from the Eastern bloc countries in the mid-1960s led to speculation 
that they were either hermaphrodites or men disguised as women. In response, 
a chromosome test was initiated in 1967 at the European Cup 
1968 
DEATH: Soccer player Jean-Louis Quadri collapses during a game in France.  
He is pronounced dead on arrival to hospital.  His autopsy reveals 
amfetamines are in his system. 
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1968 DEATH: Cyclist, Yves Mottin, died from 'excessive amphetamine use' two days 
after winning a race   
late 1960's 
Blood doping by the reinfusion of an athlete's own concentrated oxygen-
carrying red blood cells or those of a typed-matched donor, shortly before 
competition is thought to have begun. 
1969 
First application of RIA for the measurement of steroids in biological fluids 
published 
1972 
Unofficial poll taken by a 1972 Olympic Track and Field team member, Jay 
Sylvester, find that 68% of males Track and Field contestants have used 
anabolic steroids during their training. 
1973 
Two tests developed by British scientists to detect for anabolic steroids.  One 
test is by radioimmunoassay and the other is by gas chromatography couples 
with mass spectrometry.  The IOC decides to adopt both tests in tandem to 
ensure accuracy. These assays do not detect the use of testosterone. 
1974 AAS introduced as a banned class of compounds by the IOC following the 
positive screening results of the 1974 Commonwealth Games 
1976 The first female athlete tests positive for anabolic steroids at the Olympics 
Games and East German women emerge as a dominant force internationally.  
1977 
IOC meeting in Prague discusses placing "approved" drug testing labs all 
around the world. 
1980 
First assay to detect testosterone in urine to retrospectively detect doping in 
sport developed by Dr Manfred Donike.  20% of all athletes tested positive, 
including 16 gold medallists. - 1980 Olympics. 
1980's Significant improvement in mass spectrometry particularly GC-MS 
1981 First recombinant form of human hGH (rhGH) produced 
1982 
Caffeine and exogenous testosterone are added to the IOC doping list of 
prohibited substances 
1983 
First use of the testosterone / epi-testosterone ratio.  At the Pan American 
games held in Venezuela 15 athletes (including 11 weightlifters) tested 
positive.  In addition after these results were announced, 12 American track 
and field athletes withdraw and returned home before competing. 
1983 Recombinant erythropoietin produced - Patent number US 5441868 A 
1982 / 1984 
Human growth hormone (hGH) recognised to be part of doping regime for body 
builders. hGH described as the 'fad anabolic drug' of the Los Angeles Olympic 
Games. 
1984 
Beta blockers used by most pentathlon competitors to reduce tremors and 
anxiety at Olympic Games.  Note: bet-blockers were not banned at this time.  
Post the Olympic Games, 24 members of the US men's cycling team admitted 
to blood doping prior to competition.  
1984 
Media reports related to the 1984 Olympic games suggest that some athletes 
were given instructions on how to evade drug tests for anabolic steroids 
1985 Beta blockers are added to the banned substance list and blood doping is 
prohibited.  There is no test at this time however to detect blood doping. 
1985 Bio-synthetic human growth hormone manufacturing commences at Genetech 
(FDA approved). 
1986 Diuretics are added to the IOC banned substance list 
1986 
Statistical analysis of IOC approved lab positive results shows that anabolic 
steroid comprise two -thirds of drugs detected in this year and of these two-
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thirds of these positives were for nandrolone. 
1987 DEATH: West German Heptathlete, Birgit Dressel dies at the age of 26 years 
of anabolic steroid related complications.   
1988 
1988 Seoul Games, two gold medallist weightlifters tested positive for diuretics. 
1988 
Ben Johnson, winner of the 100-metre dash, tested positive for an anabolic 
steroid.  The follow-up investigation identified at least half of the athletes 
testing positive for anabolic steroids. 
1980's DEATH: Speculation that >12 deaths were the result of EPO during this 
decade.   
1988 Peptide hormones are added to the IOC banned substance list 
1989 - 1990 
Fall of communist Europe - Berlin Wall fell in late 1989 followed by the collapse 
of the GDR in 1990 and therefore the end of the GDR National doping 
program.  
1990's 
Some GDR coaches found employment with other teams including within 
China's sports programs. A number of Chinese athletes test positive during 
1990's- including 29 track and field athletes and 19 swimmers  
1991 / 1994 
Argentinian footballer, Diego Maradona, banned for 15 months in 1991 for 
testing positive for cocaine and ejected from the 1994 world cup after returning 
a positive test for ephedrine 
1994 Doping using DHT detected in 11 Chinese athletes participating in the Asian 
Games by the IOC accredited laboratory in Tokyo. 
1995 World's youngest athlete tests positive for anabolic steroid use -  a 14-year old 
female long jumper and sprinter from South Africa  
1996 
GC- HRMS testing employed for the first time at the Atlanta Olympic Games. 
1998 
Baseball player, Mark McGwire, acknowledges he uses androstenedione.  
Anabolic steroids were banned by the IOC and NCAA but not in professional 
baseball at the time of the report. 
1998 
Cyclist, Willy Voet of the Festina team, arrested by French customs police for 
transporting performance-enhancing drugs.  This arrest resulted in an 
extensive investigation which exposed the extent and 30+ year history of 
doping use in this sport.   
21st Century 
2000 
Australian Government provided a special research fund in the lead up to the 
Olympics to ensure that state of the art testing available for Sydney Olympics. 
Sydney Olympics - first to use the EPO testing by IEF.  National Measurement 
Institute of Australia’s WADA testing facility develops bases of what is now 
used for the haematology module of the ABP. 
Population studies for IRMS which allowed the first positive finding by IRMS 
during the Paralympics for testosterone 
2001 
ASDA (now ASADA) became the first National Anti-Doping Organisation to 
establish a domestic blood-testing program 
1999-2005 Lance Armstrong wins the Tour de France on seven consecutive occasions 
2000 
Three cyclists fail the mandatory health test just prior to commencement of the 
2000 Tour de France - they were not permitted to start because they had a 
haematocrit >50% 
2004 
Caffeine, probably the most popular drug in the world, is removed from the IOC 
banned substance list, notably; research indicates that the ergogenic benefits 
from caffeine ingestion may be gained from relatively low doses, including 
those attained from drinking strong coffee. 
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2004 Athens isoform assay for hGH 
2007 
BALCO investigation - Marion Jones stripped of the five medals she won at the 
Sydney Olympic games in 2000 
2009 Athlete Passport Haematological variables approved 
2012 London Olympics biomarker assay for hGH introduced 
2013 
ABP Steroidal Module approved  - monitors selected urinary steroid 
concentrations over time in order to detect steroid doping 
2013 Lance Armstrong admits to doping during his television interview with "Oprah" 
and was subsequently stripped of his seven Tour de France medals. 
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Table 3: Potential effect on test results in clinical diagnostic laboratories 1 
Measure 
Example common 
clinical lab 
method of 
detection 
Considerations for the clinical diagnostic 
laboratory 
WADA Compound group 
CORE LABORATORY TESTS 
Analyte/s 
Routine method of 
measurement 
Clinical and analytical considerations Category Drug group 
Clotting factors turbidometric 
Clinical - AAS is associated with ↑ clotting 
factors; rhEPO is associated with increased 
HCT which leads to increased viscosity and is 
believed to be associated with increased risk 
of thrombosis. 
S1 
Anabolic 
Steroids 
Full blood count   
Clinical - AAS is associated with 
polycythaemia; - rhEPO associated with 
increased RBC mass greater than the plasma 
volume, leading to an increase in haematocrit 
with some examples demonstrating HCT's 
>50% and increased reticulocytes.   
S1 / S4 
Anabolic 
Steroids / 
Hormone and 
Metabolic 
Modulators 
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Glucose 
Spectrophotometric 
/ Electrodes / 
POCT  
Clinical - AAS is associated with reduced 
glucose tolerance; B2-AR agonist drugs 
associated with an increase in circulating 
glucose; hGH is associated with bouts of 
hypoglycaemia due to the adverse effect of 
IGF-I.  
S1 / S2 / 
S3 
Anabolic 
Steroids / 
Peptides / 
Beta-2-
Agonists 
Analytical - increased Hct associated with 
inaccurate results in some POCT glucose 
meters 
S4 
Hormone and 
Metabolic 
Modulators 
GTT 
Spectrophotometric 
/ Electrodes / 
POCT  
Clinical - AAS can reduce glucose tolerance S1 
Anabolic 
Steroids 
Hct   
Clinical - EPO causes increased RBC 
production and increases haematocrit. 
Analytical - increased Hct associated with 
inaccurate results in some POCT glucose 
meters 
S4 
Hormone and 
Metabolic 
Modulators 
HDL Cholesterol Spectrophotometric Clinical - AAS is associated with ↓HDL S1 
Anabolic 
Steroids 
LDL Cholesterol 
Calculated from 
Freidwald formula 
Clinical - AAS is associated with ↑ LDL S1 
Anabolic 
Steroids 
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LFT's Spectrophotometric 
Clinical - AAS is associated with altered liver 
function and cholestatic jaundice e.g. 
increased conjugated bilirubin.  However, 
exercise alone can also increase liver function 
enzyme tests results - AST, ALT and LDH.  
S1 
Anabolic 
Steroids 
Osmolality / 
Osmol gap 
Osmometer / 
Calculated 
Clinical - no significant adverse effect from 
ethanol ingestion as levels are usually to 
enhance performance 
Analytical – no significant effect on measured 
and calculated osmol or osmol gap as 
administered levels are relatively low 
compared to recreational intake. 
P1 Alcohol 
Trigylcerides Spectrophotometric 
Clinical - AAS is associated with ↑ 
Triglycerides 
S1 
Anabolic 
Steroids 
Urine Creatinine 
Spectrophotometric 
(Jaffe or 
enzymatic) 
Clinical - increased urine volume,  
Analytical - urine concentration reduced - 
diluting everything down to potentially 
undetectable levels 
S5 Diuretics  
ENDOCRINE TESTING 
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ACTH 
Plasma 
immunoassay 
Clinical - may suppress ACTH levels due to 
negative feedback of H-P-A axis 
S9 Glucocorticoids 
Androstenedione 
Serum 
Immunoassay (a 
few LC-MS/MS) 
Clinical - DHEA administration may result in 
increased blood levels.  Analytical - androgen 
administration may possibly cross reaction in 
other C19 steroid immunoassays 
S1 
Anabolic 
Steroids 
Cortisol 
Serum 
Immunoassay (a 
few LC-MS/MS) 
Clinical - chronic glucocorticoid use may 
suppress endogenous cortisol production. 
Analytical - may cross react in immunoassays 
measuring cortisol, resulting in higher levels 
S9 Glucocorticoids 
Epi-testosterone serum LC-MMS 
Analytical - immunoassay . The C3 epimer of 
testosterone will cross react in testosterone 
immunoassays and it is structurally nearly 
identical possessing the same number of 
carbon, oxygen and hydrogen atoms.  
Analytical - Mass spectrometry.  Need to 
ensure chromatographic separation as this 
compound is the C3 epimer of testosterone 
and shares the same molecular weight and 
ion transitions. 
S1 
Anabolic 
Steroids 
FSH 
Serum/plasma 
immunoassay, can 
also be measured 
in urine but 
infrequently 
performed 
In males suppress the hypothalamic-pituitary-
testicular axis (HPT) reducing the levels of the 
gonadotrophic hormones, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH), 
which reduces the levels of circulating 
endogenous testosterone   
S1 
Anabolic 
Steroids 
Page 46 of 71
Annals of Clinical Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
DOI: 10.1177/0004563215609952
 by guest on Septem
ber 28, 2015
a
cb.sagepub.com
D
ow
nloaded from
 
47 
 
Growth 
Hormone 
Serum 
Immunoassay 
Clinical - usually as recombinant growth 
hormone; effect on growth and metabolism 
Analytical - effect will depend on if 
immunoassay detects rhGH 
S2 
Peptide 
hormones, 
growth factors 
and related 
substances 
Insulin Immunoassay  Clinical - AAS is associated with ↑ Insulin S1 
Anabolic 
Steroids 
LH 
Serum/plasma 
immunoassay, can 
also be measured 
in urine but 
infrequently 
performed 
In males suppress the hypothalamic-pituitary-
testicular axis (HPT) reducing the levels of the 
gonadotrophic hormones, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH), 
which reduces the levels of circulating 
endogenous testosterone   
S1 
Anabolic 
Steroids 
Oestrogen 
Serum/ plasma 
immunoassay  
Clinical - serum oestrogen concentrations can 
increase with androstenedione administration.  
This effect is significant for males and may be 
associated with gynaecomastia. 
S1 
Anabolic 
Steroids 
SHBG 
Serum/plasma 
immunoassay 
Exogenous AAS can result in a decrease in 
the main binding protein for testosterone i.e. 
SHBG 
S1 
Anabolic 
Steroids 
Testosterone 
Serum 
Immunoassay (a 
few LC-MS/MS) 
 hCG can increase testosterone production in 
males. In males and females the circulating 
concentration of testosterone may increase 
following testosterone administration.  
Androstenedione administration can lead to 
altered testosterone to epi-testosterone ratio. 
S1 
Anabolic 
Steroids 
Page 47 of 71
Annals of Clinical Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
DOI: 10.1177/0004563215609952
 by guest on Septem
ber 28, 2015
a
cb.sagepub.com
D
ow
nloaded from
 
48 
 
Urine steroid 
metabolomic 
profile 
Urine timed or 
random by GC-MS 
Clinical - urine concentration of androsterone 
and eticholanolone and associated 6 alpha 
and beta metabolites are increased with 
androstenedione administration ; Analytical - 
detection of "unknown" steroid peaks in 
GCMS scans associated with androgen and 
glucocorticoid administration 
S1 / S9 
Anabolic 
Steroids / 
Glucocorticoids 
1 
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 1 
Table 4.  Case examples highlighting the dilemma occasionally faced by clinical diagnostic 2 
laboratories.  3 
CASE ONE 
Clinical Notes and History:  28 y.o. male elite athlete has a routine check-up post a major 
event two days earlier.  The patient was well and had a previous routine check-up with a 
serum testosterone level of 9.9 nmol/L.  For the current check-up the patient returned the 
following results   
Analyte (Serum) Result Reference Interval 
Testosterone 3.3 nmol/L 9.9 – 27.8 
SHBG 30 nmol/L 15 – 45 
Calculated Free 
Testosterone 
64 pmol/L 260 – 740 
Creatinine Kinase 1518 U/L <195 
FSH 3 U/L 1 – 15 
LH <1 U/L 1 – 9 
Differential Diagnoses Considered: 
1) Timing of testosterone sampling.  The sample was collected in the morning 
excluding diurnal variation as the cause of the low testosterone result.  
2) Male hypogonadism.  This could be due to either hypothalamic/pituitary or 
testicular failure.  In this athlete the LH was low indicating the cause was either 
hypothalamic or pituitary origin.  i.e. hypogonadotrophic hypogonadism.  This 
resulted in consideration of: 
a) Pituitary function including TSH, prolactin and hGH and their relevant 
peripheral hormones.  Consideration during these investigations were 
given to the possibility of a pituitary tumour.  No abnormality was 
detected. 
b) Hypothalamic dysfunction.  This commonly eventuates in relation to 
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some form of trauma or in specific diseases.  All likely scenarios were 
ruled out in this patient. 
c) Drug or exercise induced hypothalamic suppression.  In such cases the 
decrease in testosterone levels is transient and will return to normal 
levels over time.  This was considered likely in this patient.  A repeat 
(follow up) testosterone level returned a result of 11.1 nmol/L. 
Summary Comments:  The testosterone level was likely to be decreased due to the recent 
exercise.  This athlete’s earlier testosterone was also borderline low.  The patient had a 
negative drug history and normal SHBG and FSH levels.  The author of this case thought 
that the transient nature of this patient’s low testosterone levels made drug abuse less 
likely, but not completely ruled out. 
Reference: Sacks S. Australasian Association of Clinical Biochemists - Omniscience case 
series. Clinical Biochemist Newsletter.  December 2009, p 51-52. 62 
 1 
CASE TWO 
Clinical Notes and History:  16 y.o. male presented to a paediatrician with a 6/12 history of 
fatigue, disturbed sleep and anxiety.  He had commenced duloxetine hydrocholride 4 
months ago.  He entered puberty at 13 years and was considered to have normal 
virilisation with Tanner Stage V noted.  He had lost weight associated with a decreased 
caloric intake over the six month period  with his BMI decreasing from 23.8 to 18.1 Kg/m2 
“The patient stated that his main interests were body building and healthy eating”.  During 
the consultation he requested for his testosterone level to be tested. 
Analyte (Serum) Result Reference Interval 
Testosterone 0.9 nmol/L 8.0 – 26.0 
SHBG 62 nmol/L 13 – 71 
FSH 4.3 U/L 1.4 – 18.0 
LH 0.9 U/L 1.4 – 7.0 
Additional Testing: 
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This low testosterone level was not consistent with the patient’s Tanner stage of V.  A 
repeat test for testosterone and SHBG was performed three weeks later and the results 
were now within the reference intervals. 
Differential Diagnoses Considered: 
1) Secondary Hypogonadism due to a hypothalamic-pituitary-gonadal tumour.  This 
patient did not exhibit any symptoms such as increased intracranial pressure and 
the MRI of the brain did not find any abnormality. Hyperprolactinaemia due to e.g. 
a prolactin producing tumour.  Prolactin is known to suppress GnRH.  This patient 
had prolactin measured on subsequent bloods which returned slightly elevated 
(but insignificant) levels compared to the reference intervals.   
2) Patient’s current medication.  Whilst this may contribute it was felt that duloxetine 
hydrochloride was unlikely to suppress the testosterone to the level observed.  The 
patient remained on this medication throughout these investigations, during which 
time the patient’s testosterone returned to “normal” male levels i.e. 16.7 – 27.8 
nmol/L. 
3) Eating disorder – males with anorexia nervosa exhibit significantly lower 
testosterone levels.  This was a likely cause in this patient based on his recent 
weight loss and “healthy” eating.  In males muscle dysmorphia is a recently 
recognised condition precipitating anorexia nervosa. 
4) Excessive exercise – overtraining syndrome, strenuous exercise etc are known to 
result in transient low levels of testosterone as discussed in patient one above.  
This was also likely in this patient.  This also results in a decrease in LH (and FSH) 
and increase in SHBG (but usually not above the reference interval). 
5) Anabolic steroid induced hypogonadism.  Based on the patient’s history this was 
also thought to be likely.  AAS suppresses natural androgen production by 
providing feedback to the hypothalamus / pituitary resulting in a decreased LH etc.  
The patient however denied on direct questioning the use of any AAS. 
 
Summary Comments:  As with patient one, both the testosterone and LH were low with a 
SHBG within the reference interval.  The authors of this case thought that the transient low 
testosterone in this patient was likely to be due to the eating disorder, potentially 
compounded by AAS (even though use denied). 
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Reference: Woodhill I, Cooper C, Zacharin M, Cukier K, Vuillermin P. Low testosterone in 
a male adolescent bodybuilder: Which diagnosis holds more weight? J Paed Child Health. 
2014;50:739-741.63 
 1 
2 
Page 53 of 71
Annals of Clinical Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
DOI: 10.1177/0004563215609952
 by guest on September 28, 2015acb.sagepub.comDownloaded from 
54 
 
 1 
 2 
 3 
 4 
 5 
 6 
Figure 1: Prevalence of sport related drug use.  Data taken from the 2013 WADA report 7 
which included the results of 269,878 samples analysed during 2013 of which 5,962 (2.21%) 8 
indicated an adverse or atypical finding.14  The pie chart in this figure demonstrates the 9 
breakdown of this 2.21% of findings. 10 
 11 
12 
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 1 
 2 
Figure 2:  Endogenous steroid pathway providing a succinct overview of the relationship of 3 
steroid hormones to each other and the likely matrix for measurement (blood or urine) in the 4 
clinical diagnostic laboratory.61 5 
  6 
 7 
8 
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